Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment"

Int J Tuberc Lung Dis. 2021 Apr 1;25(4):328-329. doi: 10.5588/ijtld.21.0006.

Authors

V Cox¹, L Guglielmetti², C Hewison², A Reuter³, J Furin⁴

Affiliations

¹ Center for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
² Médecins Sans Frontières, Paris.
³ Médecins Sans Frontières, South Africa.
⁴ Harvard Medical School, Department of Global Health and Social Medicine, Boston, MA, USA <email></email>, Email: jennifer_furin@hms.harvard.edu.

PMID: 33762080
DOI: 10.5588/ijtld.21.0006

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibiotics, Antitubercular* / therapeutic use
Human Rights
Humans
Rifampin
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antibiotics, Antitubercular
Rifampin